Atea ends 2025 with $301.8M cash; Phase 3 HCV data due mid-2026; HEV program advancing

Atea Pharmaceuticals, Inc.

Cash and investments $301.8M at Dec 31, 2025; cash runway expected through 2027.
Phase 3 HCV C-BEYOND topline results mid-2026; C-FORWARD results year-end 2026.
HEV Phase 1 study for AT-587 planned mid-2026; preclinical shows potent nanomolar anti-HEV activity.
Market survey of 153 top DAA prescribers supports need for new HCV regimen; global HCV market ~$3B net sales annually.
Atea will evaluate strategic transactions and global commercialization options to maximize reach.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.